Chemotherapy and blinatumomab improves survival for patients with B-cell acute lympho

(University of Texas M. D. Anderson Cancer Center) A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL).
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news